Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03

Inclusion Criteria:

1. Males and females that received both vaccinations and completed the Study Termination
visit in the primary study, V102_03;

2. Individuals or the individual's parents or legal guardian who have given written
consent after the nature of the study has been explained according to local
regulatory requirements;

3. Individuals who have given written assent as required by local regulations after the
nature of the study has been explained to them according to local regulatory
requirements;

4. Individuals in good health as determined by the outcome of medical history, physical
examination and clinical judgment of the investigator;

5. Individuals and/or or the individual's parents or legal guardian who can comply with
study procedures and are available for follow-up.

Exclusion Criteria:

1. History of any meningococcal vaccine administration other than the vaccination
administered in the primary study, V102_03;

2. Current or previous, confirmed or suspected disease caused by N. meningitidis;

3. Household contact with and/or intimate exposure to an individual with any laboratory
confirmed N. meningitidis infection within 60 days of enrollment;

4. History of severe allergic reactions after previous vaccinations or hypersensitivity
to any vaccine component;

5. All sexually active females that have not used an "acceptable contraceptive
method(s)" for at least 2 months prior to study entry. Acceptable birth control
methods are defined as one or more of the following:

1. Hormonal contraceptive (such as oral, injection, transdermal patch, implant,
cervical ring)

2. Barrier (condom with spermicide or diaphragm with spermicide) each and every
time during intercourse Intrauterine device (IUD)

d. Monogamous relationship with vasectomized partner. Partner must have been
vasectomized for at least six months prior to the subject's study entry;

6. Sexually active females that refuse to use to an "acceptable contraceptive method"
through to 3 weeks following the study vaccination;

7. Female subjects with a positive pregnancy test prior to the study vaccine being
administered;

8. Nursing (breastfeeding) mothers;

9. Individuals with a history of illness or with an ongoing illness that, in the opinion
of the investigator, may pose additional risk to the subject if he/she participates
in the study;

10. Any serious, chronic, or progressive disease (e.g., neoplasm, diabetes, cardiac
disease, hepatic disease, progressive neurological disease or seizure disorder;
autoimmune disease, HIV infection or AIDS, blood dyscrasias, bleeding diathesis,
signs of cardiac or renal failure, or severe malnutrition);

11. Subjects who required chronic administration (defined as more than 14 days) of
immunosuppressants or other immune-modifying drugs within six months prior to the
study vaccination. (For corticosteroids, this means prednisone, or equivalent,
≥20mg/day. Inhaled and topical steroids are allowed).

12. Receipt of blood, blood products and/or plasma derivatives, or a parenteral
immunoglobulin preparation within the previous 90 days;

13. Individuals participating in any clinical trial with another investigational product
30 days prior to first study visit or intent to participate in another clinical study
at any time during the conduct of this study;

14. Administration or planned administration, of any vaccine not foreseen by the study
protocol within 30 days prior study vaccination, and up to 30 days after the
vaccination (with the exception of any licensed influenza vaccine which may be
administered >14 days preceding or >14 days following the study vaccination);

15. Individuals who study personnel or immediate family members of study personnel
including brother, sister, child, parent, or the spouse.

16. Individuals who have experienced moderate or severe acute infection and/or fever
(defined as temperature >38°C) within 3 days prior to enrolment.

17. Who have received systemic antibiotic treatment within 7 days prior to enrolment.